2.1簇鸭坦布苏病毒灭活疫苗的免疫原性与保护效力
本研究评估新开发的2.1簇鸭坦布苏病毒灭活疫苗在鸭中的免疫原性与保护效力,采用一剂与两剂方案,并检测对1簇和3簇病毒的交叉免疫应答。结果显示两种方案均完全防御同源2.1簇强毒攻击的临床发病与死亡,两剂方案免疫应答更强更快、病理损伤更轻、病毒载量与排毒更低,且诱导对1簇和/或3簇的交叉体液与细胞免疫,但异源保护力未知。
要点
- 2.1簇DTMUV灭活疫苗一剂或两剂均完全保护同源强毒攻击的发病与死亡。
- 两剂方案比一剂方案诱导更强更快的回忆性免疫应答,更好降低组织病毒载量与排毒。
- 疫苗诱导对1簇和/或3簇的交叉中和抗体与T细胞交叉反应,异源保护力待体内攻击试验验证。
核心结论
- 2.1簇DTMUV灭活疫苗是同源保护的有前景候选疫苗,两剂方案免疫效果优于一剂。
研究设计与样本
- 在鸭中评估新开发2.1簇DTMUV灭活疫苗的一剂与两剂免疫方案,检测同源2.1簇强毒攻击后的免疫原性与保护效力,并测定对1簇和/或3簇病毒的交叉中和抗体与T细胞交叉反应。
主要发现
- 一剂和两剂方案均对致死性同源2.1簇DTMUV攻击提供完全临床保护,免于发病和死亡。
- 两剂方案比一剂方案诱导更强更快的回忆性适应性免疫应答,对病理损伤的保护更优,更有效降低靶组织病毒载量和病毒排毒。
- 疫苗尤其在两剂方案下诱导针对1簇和/或3簇的交叉反应性体液和细胞免疫应答。
临床怎么用
- 在2.1簇DTMUV流行区,可优先考虑两剂方案以获得更强更快的免疫应答和更好的病理与排毒控制。
- 对1簇或3簇DTMUV的交叉保护不能仅凭交叉免疫应答推断,需体内攻击试验确认。
局限性
- 疫苗对异源1簇和/或3簇病毒的体内保护效力尚未确定,需进一步攻击试验研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Duck Tembusu virus (DTMUV) is an emerging flavivirus causing neurological disease and severe egg drop syndrome in ducks, resulting in significant economic losses across Asia. Most current DTMUV vaccine candidates are derived from cluster 2.2 Chinese strains, while vaccines targeting other circulating clusters, particularly those prevalent in Thailand, remain unavailable. Given the marked antigenic differences among DTMUV clusters, which may limit cross-protection, the development of region-specific vaccines is urgently needed. Here, we evaluated the immunogenicity and protective efficacy of a newly developed inactivated cluster 2.1 DTMUV vaccine using one- and two-dose regimens in ducks and assessed its ability to induce cross-genotype immune responses by measuring cross-neutralizing antibody responses and T-cell cross-reactivity against heterologous cluster 1 and/or cluster 3 viruses. Our results demonstrated that both vaccination regimens provided complete clinical protection against morbidity and mortality following lethal homologous cluster 2.1 DTMUV challenge. However, the two-dose regimen elicited stronger and more rapid anamnestic adaptive immune responses, conferred superior protection against pathological lesions, and more effectively reduced viral loads in target tissues and viral shedding compared with the one-dose regimen. Furthermore, the vaccine, particularly under the two-dose regimen, induced cross-reactive humoral and cellular immune responses to clusters 1 and/or 3; however, its ability to confer heterologous protection remains unknown and warrants further investigation through in vivo challenge studies. Taken together, these results highlight the inactivated cluster 2.1 DTMUV vaccine as a promising and effective candidate for homologous protection against cluster 2.1 DTMUV in ducks.
引用
- Rungprasert K, Areeraksakul P, Tunterak W, et al. Immunogenicity and protective efficacy of an inactivated cluster 2.1 duck Tembusu virus vaccine in ducks: Evidence of cross-genotype immune responses. Vaccine. 2026. PMID: 42320385. doi:10.1016/j.vaccine.2026.128867
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。